MayMag Biologics- USA-based CMO Insulin Autopen Manufacturing Partner
MayMag Biologics-Leading federal Biologic CDMO Partner for SAM.gov Subcontractor, Biomanufacturer, federal pharmaceutical CDMO partner, GSA/SAM registered biologic manufacturer, FAR-compliant contract manufacturing Pharma for NAICS 325414 Biological Products, NAICS 325412 Pharmaceutical Preparations, 6505 Biologicals, and Formal Compounds, AI14 Defense R&D; medical pharmaceuticals; domestic biomanufacturing supply chain, Berry Amendment-compliant pharmaceuticals, TAA-compliant drug manufacturing, USA-based cGMP contract development and manufacturing organization (CDMO) offering Sterile injectable fill-finish services.
MayMag Biologics is the No. 5 Leading Insulin Self-Injection Device OEM & 3 mL cartridge insulin delivery pen manufacturer with 506 (e) registration with the USFDA. Premier GLP-1 Peptide Pen Injector Contract Manufacturing. A Leading Biologics CDMO For Insulin API And Large-Scale Recombinant Protein Production to Capture Global Insulin Market Share. MayMag Biologics Is Your Recombinant Insulin API Supplier and Autoinjector CDMO Manufacturing Partner For Large-Scale Biologics Manufacturing Targeting FDA Approval For Interchangeable Biosimilar Insulin.
MayMag Biologics Provides 21 CFR 4 Combination Product Contract Manufacturing, GLP-1 Pen Injector Supplier Services, And Annex 1-Compliant Sterile Fill-Finish Syringes. Premier Biologics Drug Delivery Device Contract Manufacturer and Insulin Pen OEM Supplier. Experts In Sterile Fill-Finish, Prefilled Syringes, Biologics, Epinephrine, And Autoinjectors. Accelerate Delivery with MayMag Biologics—Your Custom Pen Injector Device Developer and High-Volume Autoinjector Assembly Supplier, The Leading Biologics Drug Delivery Device Contract Manufacturer.
MayMag Biologics is a USA-based CMO Insulin Manufacturing Partner, Providing API Insulin Autopen Combination Drug Large-Scale Recombinant Protein Production to Capture Global Insulin Market Share. MayMag Biologics Is Your Recombinant Insulin API Supplier & Autoinjector CDMO Manufacturing Partner for Large-Scale Biologics Manufacturing Targeting Interchangeable Biosimilar Insulin FDA Approval.
Scale With MayMag Biologics, A Premier Biologics Drug Delivery Device Contract Manufacturer & Insulin Pen OEM Supplier. They Are Experts in Sterile Fill-Finish, Prefilled Syringes, Biologics, And Autoinjectors. MayMag Biologics expands CDMO sterile fill-finish for biosimilar insulins (Icodec, Degludec, Glargine, Detemir, Aspart) in auto-pens & vials to lower global healthcare costs. MayMag Biologics-Elite Biopharmaceutical Parenteral Delivery Device Supplier. Experts in ISO 13485 Cleanroom Device Assembly Services & Commercial-Scale Insulin Device Manufacturing.
MayMag Biologics is a Dallas, Texas-based FDA-registered 506(e) outsourcing facility and contract development and manufacturing organization (CDMO) specializing in sterile biologics, FDA-shortlisted drugs, auto-pen fill-finish, peptide API synthesis, sterile injectable compounding, biosimilar drug manufacturing, bacteriostatic water for injection (BWFI), and auto-injection device production.
Operating under cGMP standards (21 CFR
Parts 210–211), ISO 13485 certification, and USP Chapter <797> and
<800> compliance, MayMag Biologics provides pharmaceutical sponsors,
research institutions, compounding pharmacies, and specialty distributors with
a fully domestic U.S. supply chain for complex drug products — eliminating
dependence on overseas API manufacturers.
Core manufacturing capabilities
include solid-phase peptide synthesis (SPPS) for GLP-1 agonists including
tirzepatide and semaglutide analogs; large-volume sterile injectable
fill-finish; biosimilar compounding for insulin analogs and GLP-1/GIP dual agonists;
bacteriostatic water for injection (BWFI) in multi-dose vials; epinephrine
auto-injectors; insulin pens; rheumatoid arthritis autoinjectors; and MDI/DPI
inhalation therapeutics.
MayMag Biologics operates dual
cGMP-certified facilities in the Dallas–Fort Worth metroplex (Dallas and
Garland, Texas) and serves clients nationwide. As a registered 506(e)
outsourcing facility under the Drug Quality and Security Act (DQSA), MayMag
operates under direct FDA oversight — distinct from traditional state-regulated
compounding pharmacies.
Partner with MayMag Biologics for
Commercial-Scale Insulin Device Manufacturing, ISO 13485 Cleanroom Device
Assembly Services, and custom High-Volume Autoinjector supply; insulin and
Biosimilar insulin manufacturers in the USA.
What sets MayMag Biologics apart from other pharma companies is:
·
Our position as a leading EpiPen insulin biosimilar
injector pen manufacturer.
·
We are local, based in the United States, with stringent
drug quality control and monitoring.
·
Our scale, facility redundancy, and robust device supply
chain mean we can meet 100% of your market demand without any backorders,
leveraging multiple FDA-compliant, GMP-certified facilities for both the active
drug substance and the 'fill-finish' final step.
·
As one of the top insulin pen manufacturers, we understand
how to handle the stability requirements of large batches, from formulation
through transportation, without risking product degradation.
·
Additionally, MayMag excels in injection pen contract
manufacturing by maintaining device continuity assurance with in-house 510k
auto device pen manufacturing, clean FDA Form 483 records, and zero warning
letters.
·
MayMag biologics is the only 506e large-scale manufacturer
of FDA short-listed drugs in the USA, serving the federal government and
contract awardees, providing affordable, low-cost generics and biosimilar
sterile injectable biologics, oral solid dosages, and OTCs

Comments
Post a Comment